A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
A Phase I, Open, Multicenter Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
Malignant Pleural Effusion
DRUG: JMKX000197
Incidence of dose limiting toxicity, Up to approximately 7 days at each dose level|Maximum tolerated dose, Up to approximately 24 months|Recommended Phase II dose, Up to approximately 24 months
Objective Response Rate（ORR）, Up to approximately 36 days|Disease control rate, DCR, Up to approximately 36 days|Maximum observed concentration (Cmax) of JMKX000197, Up to approximately 7 days|Time to maximum concentration (Tmax) of JMKX000197, Up to approximately 7 days|Half-life (t1/2) of JMKX000197, Up to approximately 7 days|Areas under the concentration-time curve from time zero extrapolated to infinity (AUC0-inf) of JMKX000197, Up to approximately 7 days|Areas under the concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t) of JMKX000197, Up to approximately 7 days|Amount of Drug Excreted Via Urine and excrement During the Collection Interval 0-48 Hours Post Administration, Up to approximately 48 hours|Concentrations of IL-6 in plasma, Up to approximately 36 days
Primary objectives: To evaluate the safety and tolerability of JMKX000197 injection in the treatment of patients with malignant pleural effusion, explore DLT of JMKX000197 treatment, and determine MTD and RP2D.

Secondary objectives: To evaluate the pharmacokinetic (PK)/pharmacokinetic (PD) characteristics of JMKX000197 injection in the treatment of patients with malignant pleural effusion; To evaluate preliminarily efficacy of JMKX000197 injection in patients with malignant pleural effusion; To evaluate the drug metabolic transformation of JMKX000197 injection.